Glucagon-like peptide-1 plasmid construction and delivery for the treatment of type 2 diabetes (Q46615413)

23 December 2017

title

Glucagon-like peptide-1 plasmid construction and delivery for the treatment of type 2 diabetes (English)

1 reference

23 December 2017

0 references

Suna Choi

1

1 reference

23 December 2017

Seungjoon Oh

series ordinal

2

1 reference

23 December 2017

Minhyung Lee

series ordinal

3

1 reference

23 December 2017

Sung Wan Kim

series ordinal

4

1 reference

23 December 2017

publication date

21 July 2005

1 reference

23 December 2017

published in

Molecular Therapy

1 reference

23 December 2017

volume

12

1 reference

23 December 2017

issue

5

1 reference

23 December 2017

page(s)

885-891

1 reference

23 December 2017

Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.039

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.039

Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.039

Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.039

Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.039

Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.039

Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.039

Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.039

Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.039

Mechanisms of sulfonylurea-induced insulin release

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.039

New drug targets for type 2 diabetes and the metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.039

Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.039

Sequence requirements for plasmid nuclear import

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.039

The NF-kappa B and I kappa B proteins: new discoveries and insights

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.039

A regulated, NFkappaB-assisted import of plasmid DNA into mammalian cell nuclei

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.039

Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.039

GLP-1 gene delivery for the treatment of type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.039

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.039

Glucagon-like peptide-1: a potent regulator of food intake in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.039

A role for glucagon-like peptide-1 in the central regulation of feeding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.039

The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.039

Transfection of pancreatic-derived beta-cells with a minigene encoding for human glucagon-like peptide-1 regulates glucose-dependent insulin synthesis and secretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.039

Components of vectors for gene transfer and expression in mammalian cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.039

Poly(ethylenimine) and its role in gene delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.039

Biochemistry and molecular cell biology of diabetic complications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.039

10.1016/J.YMTHE.2005.03.039

7 January 2021

Identifiers

DOI

1 reference

23 December 2017

1 reference

23 December 2017